<DOC>
	<DOCNO>NCT01788605</DOCNO>
	<brief_summary>1 . The purpose study determine efficacy ramosetron prevention emesis control nausea vomit despite prophylactic antiemetic treatment hematopoietic stem cell transplantation 2 . The study hypothesis ramosetron effective prevention emesis control emesis and/or vomit develop prophylactic antiemetic therapy set hematopoietic stem cell transplantation</brief_summary>
	<brief_title>Efficacy Study Ramosetron Setting Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ramosetron</mesh_term>
	<criteria>1 . Patients undergoing hematopoietic stem cell transplantation condition highly moderately emetogenic drug total body irradiation ( TBI ) hematologic malignancy 2. age 18 yr 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 4. patient able take oral medication 5. patient get wellinformed sign consent 1 . Patients complicate severe hypertension ( systolic blood pressure &gt; 210 mmHg diastolic blood pressure &gt; 120 mmHg ) significant heart disease congestive heart failure renal insufficiency ( serum Cr &gt; = 3.0 mg/dL ) liver disease ( Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &gt; 3 upper normal limit ; alkaline phosphatase ( ALP ) &gt; 2 upper normal limit ) 2 . Patients complicate condition gastrointestinal obstruction active peptic ulcer cause emesis 3 . Patients brain tumor , brain metastasis epilepsy 4 . Patients history extrapyramidal symptom 5 . Patients history allergy serotonin antagonists 6. pregnant lactate woman 7 . Patients drug abuse psychiatric illness , patient capable normal communication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>hematologic malignancy</keyword>
	<keyword>hematopoietic stem cell transplantation</keyword>
	<keyword>ramosetron</keyword>
	<keyword>emesis</keyword>
</DOC>